Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease Measured after Treatment with Bispecifics in Relapsed Multiple Myeloma: Experience from an Academic Medical Center

Alberto Blanco, Ajai Chari, Thomas G Martin, Shagun Arora, Alfred Chung, Anupama Deepa Kumar, Nina Shah, Sandy W. Wong, Hiroyuki Takamatsu, Joaquin Martínez-López, Jeffrey Lee Wolf

Blood (2024) 144 (Supplement 1): 7020.

https://doi.org/10.1182/blood-2024-203768

Published: 2024

Journal Articles

Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)

David H. Vesole, Thomas G Martin, Suzanne Trudel, Henning Schade, Samantha Shenoy, Noa Biran, Jeffrey Lee Wolf, Jeffrey V Matous, Pamela Munster, Savannah Berkeley, Jesús G Berdeja

Blood (2024) 144 (Supplement 1): 1982.

https://doi.org/10.1182/blood-2024-209597

Published: 2024

Journal Articles

Germline Variation Predicts Treatment Response in Multiple Myeloma

Kyle Roter, BSc, Donglei Hu, PhD, Alyssa Clay-Gilmour, PhD, Scott Huntsman, Nina D. Shah, MD, Sandy W. Wong, MD, Thomas G. Martin, III, MD, Jeffrey Lee Wolf, MD, Moritz Binder, MDMPH, Shaji K. Kumar, MD, S. Vincent Rajkumar, MD, Susan L. Slager, PhD, Celine M. Vachon, PhD, Elad Ziv, MD

Blood (2019) 134 (Supplement_1): 4397.

https://doi.org/10.1182/blood-2019-129344

Published: 2019

Journal Articles

Retrospective Analysis of Modified Hyper-CVAD Therapy Combined with Proteasome Inhibition for Patients with Multiple Myeloma and Renal Insufficiency or Renal Failure

Derek Galligan, MD, Rupa Narayan, MD, Sarah Kim, PharmD, Ann Lazar, PhD MS, Marisela Tan, PharmD, Richard Fong, PharmD, Mimi Lo, PharmD, Nina Shah, MD, Shagun Arora, MD, Sandy W. Wong, MD, Thomas G. Martin, III, MD, Jeffrey Lee Wolf, MD

Blood (2018) 132 (Supplement 1): 3236.

https://doi.org/10.1182/blood-2018-99-111625

Published: 2018

Journal Articles

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

Blood (2017) 130 (Supplement 1): 395.

https://doi.org/10.1182/blood.V130.Suppl_1.395.395

Published: 2017

Journal Articles

Autologous Transplantation Is Safe and Effective For Patients With Multiple Myeloma Related Renal Insufficiency

Claire C Greene, BA, Jimmy Hwang, PhD, Jeffrey Lee Wolf, MD, Lloyd E Damon, MD, Anuj Mahindra, MD, Thomas G Martin, III, MD

Blood (2013) 122 (21): 3388.

https://doi.org/10.1182/blood.V122.21.3388.3388

Published: 2013

Journal Articles

A Meta-Analysis Of Genome-Wide Association Studies Of Multiple Myeloma In Cases and Controls Of European Origin Identifies a Risk Locus In 12q23.1

Kristin A Rand, Ph.D., M.P.H., Nicola Camp, PhD, Alessandro Martino, Ph.D., Eric W. Dean, MD, Daniel J. Serie, Ph.D., Christopher K. Edlund, M.S., Donglei Hu, M.S., Karen Curtin, Ph.D., Scott Huntsman, MS, David J. Van Den Berg, Ph.D., Anneclaire De Roos, PhD, Elizabeth E Brown, Ph.D., Graham G. Giles, Ph.D., John J. Spinelli, Ph.D., Sikander Ailawadhi, M.D., Brenda M. Birmann, ScD, Angela R Brooks-Wilson, Ph.D., Richard K Severson, PhD, Paige M Bracci, PhD, Mulugeta Gebregziabher, PhD, Michael H. Tomasson, MD, Ann M. Mohrbacher, MD, Guido J. Tricot, M.D., Ph.D., Daniele Campa, M.D., Ph.D., Thomas Martin, III, M.D., Brian E. Henderson, M.D., Maurizio Zangari, MD, Nathaniel Rothman, MD, MPH, MHS, Stephen Jacob Chanock, MD, Shaji Kumar, MD, Laurence N. Kolonel, MD, PhD, Jeffrey Lee Wolf, MD, Graham A Colditz, M.D., Dr.PH., S. Vincent Rajkumar, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Christopher Haiman, Sc.D., David V. Conti, Ph.D., Federico Canzian, PhD, Celine M Vachon, PhD, Elad Ziv, MD, Wendy Cozen, D.O., M.P.H.

Blood (2013) 122 (21): 3111.

https://doi.org/10.1182/blood.V122.21.3111.3111

Published: 2013

Journal Articles

Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial

Blood (2011) 118 (21): 815.

https://doi.org/10.1182/blood.V118.21.815.815

Published: 2011

Journal Articles

Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results.

Blood (2009) 114 (22): 1869.

https://doi.org/10.1182/blood.V114.22.1869.1869

Published: 2009

Journal Articles

A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma

Jeffrey Lee Wolf, David Siegel, Jeffrey Matous, Sagar Lonial, Hartmut Goldschmidt, Stefan Schmitt, Ravi Vij, Margarida De Malgalhaes-Silverman, Rafat Abonour, Muhammad Jalaluddin, Martha Li, Katharine Hazell, Priscille M. Bourquelot, Maria-Victoria Mateos, Kenneth C. Anderson, Andrew Spencer, Jean-Luc Harousseau, Joan Bladé

Blood (2008) 112 (11): 2774.

https://doi.org/10.1182/blood.V112.11.2774.2774

Published: 2008

Journal Articles

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Shaji Kumar, MD, Ian W Flinn, MD, PhD, Stephen J. Noga, MD, PhD, Parameswaran Hari, MD, MS, Robert M. Rifkin, MD, Natalie Scott Callander, MD, Manish Bhandari, MD, Jeffrey Lee Wolf, MD, Cristina Gasparetto, MD, Amrita Krishnan, MD, FACP, Daren D Grosman, MD, PhD, Jonathan Glass, MD, Entezam Asim Sahovic, MD, Hongliang Shi, MS, Iain J. Webb, MD, Paul Richardson, MD, S. Vincent Rajkumar, MD

Blood (2008) 112 (11): 93.

https://doi.org/10.1182/blood.V112.11.93.93

Published: 2008

Journal Articles

A Phase II Study of Bortezomib (Velcade ® ), Cyclophosphamide (Cytoxan ® ), Thalidomide (Thalomid ® ) and Dexamethasone as First-Line Therapy for Multiple Myeloma

William Bensinger, Sundar Jagannath, MD, Robert Vescio, MD, Elber S. Camacho, MD, Jeffrey Lee Wolf, David H Irwin, MD, Gerardo Capo, III, MD, Marti McKinley, Phyllis Potts, David H. Vesole, MD, PhD, Amitabha Mazumder, MD, Dixie-Lee Esseltine, MD, Pamela Becker, John Crowley, PhD, Brian GM Durie, MD

Blood (2008) 112 (11): 94.

https://doi.org/10.1182/blood.V112.11.94.94

Published: 2008

Journal Articles

Utility of Bortezomib Retreatment for Patients with Relapsed Multiple Myeloma.

Jeffrey Lee Wolf, MD, Paul Richardson, MD, Michael Schuster, MD, Annette LeBlanc, David Battleman, MD, MSc, Ian Walters, MD

Blood (2006) 108 (11): 3532.

https://doi.org/10.1182/blood.V108.11.3532.3532

Published: 2006

Journal Articles

Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma.

Sundar Jagannath, MD, Brian G.M. Durie, MD, Jeffrey Lee Wolf, MD, Elber S. Camacho, David Irwin, MD, Jose Lutzky, MD, Marti McKinley, BSN, Afshin Eli Gabayan, MD, Amitabha Mazumder, MD, John Crowley, PhD, Robert Vescio, MD

Blood (2006) 108 (11): 796.

https://doi.org/10.1182/blood.V108.11.796.796

Published: 2006

Journal Articles

Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Thomas E. Witzig, MD, Julie M. Vose, MD, Henry P. Kaplan, MD, Jeffrey Lee Wolf, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Peter H. Wiernik, MD

Blood (2006) 108 (11): 2482.

https://doi.org/10.1182/blood.V108.11.2482.2482

Published: 2006

NARROW

Minimal Residual Disease Measured after Treatment with Bispecifics in Relapsed Multiple Myeloma: Experience from an Academic Medical Center

Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)

Germline Variation Predicts Treatment Response in Multiple Myeloma

Retrospective Analysis of Modified Hyper-CVAD Therapy Combined with Proteasome Inhibition for Patients with Multiple Myeloma and Renal Insufficiency or Renal Failure

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

Autologous Transplantation Is Safe and Effective For Patients With Multiple Myeloma Related Renal Insufficiency

A Meta-Analysis Of Genome-Wide Association Studies Of Multiple Myeloma In Cases and Controls Of European Origin Identifies a Risk Locus In 12q23.1

Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial

Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results.

A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

A Phase II Study of Bortezomib (Velcade ® ), Cyclophosphamide (Cytoxan ® ), Thalidomide (Thalomid ® ) and Dexamethasone as First-Line Therapy for Multiple Myeloma

Utility of Bortezomib Retreatment for Patients with Relapsed Multiple Myeloma.

Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma.

Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only